Takeda’s orexin receptor 2 agonist oveporexton succeeded in two phase III trials, setting up a first FDA filing for the small molecule for the treatment of narcolepsy type 1. Other companies including ...

CHICAGO -- Novel orexin receptor 2 agonist oveporexton normalized wakefulness for most people with narcolepsy type 1 in two randomized phase III trials. Mean sleep latency across four, 40-minute ...

Brendon Yee, PhD, professor and respiratory and sleep physician, Woolcock Institute of Medical Research, discusses the success of ALKS 2680, an investigational oral selective orexin 2 receptor agonist ...

Tsukuba, Japan—Orexin, named after its role in feeding regulation, is a potent endogenous sleep/wake state regulator and is expected to play an essential role in controlling the cross-talk mechanism ...

Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, ...

— Consistent, Dose-Dependent Effects Enable Dose Selection for Evaluation in Planned Phase 2 Study — The patients with NT1 were randomized to a crossover study in which each of them received 1 mg, 3 ...

It’s not often that a pharmaceutical executive discusses a competitor’s success. Alkermes Chief Operating Officer Blair Jackson not only talks about it openly, he cheers it. Alkermes’s scope in ...

The investigational orexin receptor 2 (OX2R) agonist oveporexton improved cognitive symptoms of narcolepsy type 1 (NT1) in secondary analysis of a phase II trial. The oral agent improved attention, ...

ZÜRICH, SWITZERLAND / ACCESSWIRE / December 3, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (NLS), a biopharmaceutical company, is pleased to share preclinical data demonstrating the ...

Cognitive symptoms associated with narcolepsy type 1 are common, particularly in sustaining attention and processing information. Oveporexton improved attention, memory, and executive function over 8 ...